ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2382

Adherence to Dmards in the First Six Months of Treatment in Early Arthritis Patients; Comparing Three Adherence Measures

Annelieke Pasma1, Ethan den Boer2, Adriaan van 't Spijker3, Reinier Timman3, Jan van Busschbach3 and J.M.W. Hazes4, 1Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, 2Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, 3Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Compliance, DMARDs and Early Rheumatoid Arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose Non-adherence to DMARDs is an important indicator for the effectiveness of treatment in early arthritis patients. Reported non-adherence rates differ widely, because studies use different adherence measures. Electronic measurement is considered as a ‘gold standard’, but other measures have other attractive features. This study compared three methods to ascertain how non-adherence should be measured: the Compliance Questionnaire Rheumatology (CQR), the intracellular uptake of methotrexate (MTX) in the form of methotrexate-polyglutamates (MTX-PGs) and Medication Event Monitoring Systems (MEMS).
Methods Adult patients diagnosed with arthritis who started DMARDs were included in a cohort study. MTX-PGs were collected and the CQR was filled out after three and six months of treatment. Non-adherence was continuously measured with MEMS. When there was a discordance between the observed opening and the expected opening of the MEMS cap, this was assigned as a non-adherence event. The CQR and MEMS were compared with Pearson correlations. Sensitivity and specificity of adherence measured with MEMS against a CQR discriminant cut-off score was calculated at three and six months. To assess the influence of adherence measured with MEMS on MTX-PGs, a multivariate linear regression (backward selection) with MTX-PGs as dependent variable and with non-adherence measured with MEMS the 12 weeks before MTX-PG measurement (continuous score), age, gender, time of treatment and dosage as independent variables was performed.
Results Two hundred and one patients entered the study. As measured with MEMS, non-adherence rates varied over time and between different DMARDs (figure 1). For sulfasalazine and hydroxychloroquine, the non-adherence rates were highest. For all medicines, except for prednisone, the non-adherence rate rose over time. The CQR did not correlate with MEMS at any of the time points of therapy. At both time points, the ROC curves showed no discrimination between non-adherence measured with MEMS against the CQR cut-off score. Non-adherence (B 0.548, p=0.035), time of treatment (B 0.947, p=0.006) and age (B 2.052, p<0.000) significantly contributed to MTX-PGs, but only accounted for 18.8% of explained variance.
Conclusion Non-adherence rates for prednisone are lowest and stable. This might be explained by the fact that patients immediately experience the effect of prednisone, and that most patients tapered prednisone. The non-adherence rate for MTX was low, probably because rheumatologists emphasize the necessity of MTX. The CQR is not associated with MEMS, but MTX-PGs are weakly associated with MEMS. This can be due to several reasons, such as individual differences in the uptake of MTX. We have to learn more about the uptake of MTX over time per patient, before we can use MTX-PGs in daily practice as a non-adherence measure.


Disclosure:

A. Pasma,
None;

E. den Boer,
None;

A. van ‘t Spijker,
None;

R. Timman,
None;

J. van Busschbach,
None;

J. M. W. Hazes,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adherence-to-dmards-in-the-first-six-months-of-treatment-in-early-arthritis-patients-comparing-three-adherence-measures/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology